On September 25, 2026, B. Riley Securities initiated coverage of Precigen (NASDAQGS:PGEN) with a Buy recommendation. At the close on that date, Precigen’s stock was priced at $7.75, recently slightly up from $7.70 on September 24, 2026.
Precigen, a U.S.-based biotechnology firm, specializes in gene and cell therapies, addressing serious conditions like cancer and metabolic disorders. The company reported its latest earnings on August 4, 2026, showing revenue of approximately $54.98 million, surpassing expectations of $28.39 million, and an EPS of $0.05 compared to an estimate of -$0.0136.
As of September 15, 2026, the consensus target price for Precigen stood at $14.79, implying a potential upside of 90.84% from its recent trading price. Currently, there are 9 total recommendations for the company with a positive consensus of 77.8% classified as strong buy or buy.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
